Published in JAMA on September 22, 2010
Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med (2012) 3.93
Danazol Treatment for Telomere Diseases. N Engl J Med (2016) 3.39
TERC polymorphisms are associated both with susceptibility to colorectal cancer and with longer telomeres. Gut (2011) 2.75
How I treat acquired aplastic anemia. Blood (2012) 2.44
Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood (2013) 1.97
Short leukocyte telomere length predicts risk of diabetes in american indians: the strong heart family study. Diabetes (2013) 1.91
Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome. Blood (2014) 1.82
Bone marrow failure and the telomeropathies. Blood (2014) 1.23
Short telomeres result in chromosomal instability in hematopoietic cells and precede malignant evolution in human aplastic anemia. Leukemia (2011) 1.21
Direct comparison of flow-FISH and qPCR as diagnostic tests for telomere length measurement in humans. PLoS One (2014) 1.11
Short telomeres: from dyskeratosis congenita to sporadic aplastic anemia and malignancy. Transl Res (2013) 1.08
Age-adjusted recipient pretransplantation telomere length and treatment-related mortality after hematopoietic stem cell transplantation. Blood (2012) 1.01
Clinical management of aplastic anemia. Expert Rev Hematol (2011) 0.95
Telomere dynamics in mice and humans. Semin Hematol (2013) 0.92
Telomere attrition and candidate gene mutations preceding monosomy 7 in aplastic anemia. Blood (2014) 0.91
The complex pathophysiology of acquired aplastic anaemia. Clin Exp Immunol (2015) 0.91
Telomeres in disease. F1000 Med Rep (2012) 0.87
Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia. Leukemia (2015) 0.85
Shorter telomere length in peripheral blood leukocytes is associated with childhood autism. Sci Rep (2014) 0.85
Severe aplastic anemia associated with eosinophilic fasciitis: report of 4 cases and review of the literature. Medicine (Baltimore) (2013) 0.85
Success of allogeneic marrow transplantation for children with severe aplastic anaemia. Br J Haematol (2012) 0.85
Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010. Biol Blood Marrow Transplant (2010) 0.83
Highly skewed T-cell receptor V-beta chain repertoire in the bone marrow is associated with response to immunosuppressive drug therapy in children with very severe aplastic anemia. Blood Cancer J (2011) 0.83
Human telomere disease due to disruption of the CCAAT box of the TERC promoter. Blood (2012) 0.82
Recent advances in treatment of aplastic anemia. Korean J Intern Med (2014) 0.81
Peripheral blood lymphocyte telomere length as a predictor of response to immunosuppressive therapy in childhood aplastic anemia. Haematologica (2014) 0.80
Effect of race on outcomes after allogeneic hematopoietic cell transplantation for severe aplastic anemia. Am J Hematol (2013) 0.79
I walk the line: how to tell MDS from other bone marrow failure conditions. Curr Hematol Malig Rep (2014) 0.79
Paroxysmal nocturnal hemoglobinuria and telomere length predicts response to immunosuppressive therapy in pediatric aplastic anemia. Haematologica (2015) 0.79
Deep phenotyping of Tregs identifies an immune signature for idiopathic aplastic anemia and predicts response to treatment. Blood (2016) 0.78
Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation. Haematologica (2014) 0.78
The challenging world of cytopenias: distinguishing myelodysplastic syndromes from other disorders of marrow failure. Oncologist (2014) 0.77
Aplastic anemia: immunosuppressive therapy in 2010. Pediatr Rep (2011) 0.77
Treatment-related myelodysplastic syndrome: molecular characteristics and therapy. Curr Opin Hematol (2011) 0.77
Modeling Human Bone Marrow Failure Syndromes Using Pluripotent Stem Cells and Genome Engineering. Mol Ther (2015) 0.75
Expression of Shelterin component POT1 is associated with decreased telomere length and immunity condition in humans with severe aplastic anemia. J Immunol Res (2014) 0.75
Acute promyelocytic leukemia transformation in a patient with aplastic anemia: a case report with literature review. Int J Clin Exp Med (2015) 0.75
Reversibility of Defective Hematopoiesis Caused by Telomere Shortening in Telomerase Knockout Mice. PLoS One (2015) 0.75
Prolonged cyclosporine administration after antithymocyte globulin delays but does not prevent relapse in severe aplastic anemia. Am J Hematol (2014) 0.75
Telomere length and associations with somatic mutations and clinical outcomes in acute myeloid leukemia. Leuk Res (2016) 0.75
Telomere measurement by quantitative PCR. Nucleic Acids Res (2002) 18.69
Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell (1997) 13.34
Telomere reduction in human colorectal carcinoma and with ageing. Nature (1990) 11.24
Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J (1992) 10.97
Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med (2005) 7.09
Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet (2007) 6.57
The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell (2001) 5.98
Telomere diseases. N Engl J Med (2009) 5.68
Current concepts in the pathophysiology and treatment of aplastic anemia. Blood (2006) 5.20
Cancer in dyskeratosis congenita. Blood (2009) 4.28
Telomeres and telomerase in cancer. Carcinogenesis (2009) 4.28
Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA (2003) 3.90
Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell (2007) 3.23
Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. Proc Natl Acad Sci U S A (2009) 2.44
Leukocyte telomere length predicts cancer risk in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev (2007) 2.39
Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Res (2002) 2.24
Ulcerative colitis is a disease of accelerated colon aging: evidence from telomere attrition and DNA damage. Gastroenterology (2008) 2.14
Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood (2009) 2.12
Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood (2002) 2.10
Progressive telomere shortening in aplastic anemia. Blood (1998) 2.10
Telomere maintenance and human bone marrow failure. Blood (2008) 2.09
Chromosomal instability in ulcerative colitis is related to telomere shortening. Nat Genet (2002) 2.08
Telomere length in leukocyte subpopulations of patients with aplastic anemia. Blood (2001) 1.89
Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil. Br J Haematol (2006) 1.82
Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica (2009) 1.73
Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol (2006) 1.68
Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer. Clin Cancer Res (1997) 1.68
Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol (2008) 1.49
Short telomeres initiate telomere recombination in primary and tumor cells. PLoS Genet (2009) 1.21
Telomere length in peripheral blood predicts survival in clear cell renal cell carcinoma. Cancer Res (2009) 1.18
Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia. Leukemia (2009) 1.01
Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med (2005) 7.09
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med (2006) 6.90
The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology (2002) 5.70
Telomere diseases. N Engl J Med (2009) 5.68
Current concepts in the pathophysiology and treatment of aplastic anemia. Blood (2006) 5.20
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology (2015) 3.96
Hematopoietic-specific microRNA expression in human cells. Leuk Res (2005) 3.95
Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med (2012) 3.93
Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA (2003) 3.90
Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med (2011) 3.82
Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. N Engl J Med (2015) 3.42
Hybrid DNA virus in Chinese patients with seronegative hepatitis discovered by deep sequencing. Proc Natl Acad Sci U S A (2013) 3.35
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood (2007) 2.76
Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA. Lancet (2003) 2.76
Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. Blood (2003) 2.73
Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood (2006) 2.69
In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. Lancet (2004) 2.47
HIV envelope-CXCR4 signaling activates cofilin to overcome cortical actin restriction in resting CD4 T cells. Cell (2008) 2.46
How I treat acquired aplastic anemia. Blood (2012) 2.44
Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. Proc Natl Acad Sci U S A (2009) 2.44
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood (2007) 2.36
High-sensitivity C-reactive protein as an independent predictor of progressive myocardial functional deterioration: the multiethnic study of atherosclerosis. Am Heart J (2012) 2.18
Aplastic anemia. Curr Opin Hematol (2008) 2.17
Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood (2009) 2.12
Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood (2002) 2.10
Telomere maintenance and human bone marrow failure. Blood (2008) 2.09
Percentile ranking and citation impact of a large cohort of National Heart, Lung, and Blood Institute-funded cardiovascular R01 grants. Circ Res (2014) 2.08
Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood (2013) 1.97
Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. Blood (2008) 1.95
Th17 immune responses contribute to the pathophysiology of aplastic anemia. Blood (2010) 1.91
Reduced ascending aortic strain and distensibility: earliest manifestations of vascular aging in humans. Hypertension (2010) 1.91
Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation. Br J Haematol (2006) 1.88
Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol (2008) 1.84
Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil. Br J Haematol (2006) 1.82
Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. J Clin Oncol (2010) 1.79
Constitutional telomerase mutations are genetic risk factors for cirrhosis. Hepatology (2011) 1.77
Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica (2009) 1.73
Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood (2004) 1.70
Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol (2006) 1.68
Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. Leuk Res (2012) 1.65
T-bet, a Th1 transcription factor, is up-regulated in T cells from patients with aplastic anemia. Blood (2006) 1.64
Mutations in the SBDS gene in acquired aplastic anemia. Blood (2007) 1.62
Left ventricular global function index by magnetic resonance imaging--a novel marker for assessment of cardiac performance for the prediction of cardiovascular events: the multi-ethnic study of atherosclerosis. Hypertension (2013) 1.61
Functional characterization of natural telomerase mutations found in patients with hematologic disorders. Blood (2006) 1.57
A spectrum of severe familial liver disorders associate with telomerase mutations. PLoS One (2009) 1.57
Prevalence and incidence of hypertension in adolescent girls. J Pediatr (2010) 1.51
Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol (2008) 1.49
Analysis of T-cell repertoire in hepatitis-associated aplastic anemia. Blood (2004) 1.46
Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia. Blood (2007) 1.44
Age-related changes in aortic arch geometry: relationship with proximal aortic function and left ventricular mass and remodeling. J Am Coll Cardiol (2011) 1.42
A mouse model of lymphocyte infusion-induced bone marrow failure. Exp Hematol (2004) 1.42
Enrichment of hematopoietic stem cells with SLAM and LSK markers for the detection of hematopoietic stem cell function in normal and Trp53 null mice. Exp Hematol (2008) 1.41
Transcript profile of CD4+ and CD8+ T cells from the bone marrow of acquired aplastic anemia patients. Exp Hematol (2004) 1.40
Ex vivo-generated CD36+ erythroid progenitors are highly permissive to human parvovirus B19 replication. J Virol (2007) 1.40
Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program (2002) 1.39
The epidemiology of aplastic anemia in Thailand. Blood (2005) 1.38
Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor. Proc Natl Acad Sci U S A (2006) 1.36
Functional characterization of telomerase RNA variants found in patients with hematologic disorders. Blood (2004) 1.33
Prognostic value of myocardial circumferential strain for incident heart failure and cardiovascular events in asymptomatic individuals: the Multi-Ethnic Study of Atherosclerosis. Eur Heart J (2013) 1.32
N-terminal pro-B-type natriuretic peptide, left ventricular mass, and incident heart failure: Multi-Ethnic Study of Atherosclerosis. Circ Heart Fail (2012) 1.31
Interferon-gamma-induced gene expression in CD34 cells: identification of pathologic cytokine-specific signature profiles. Blood (2005) 1.30
Minor antigen h60-mediated aplastic anemia is ameliorated by immunosuppression and the infusion of regulatory T cells. J Immunol (2007) 1.28
Hematopoiesis in 3 dimensions: human and murine bone marrow architecture visualized by confocal microscopy. Blood (2010) 1.27
Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes. Haematologica (2010) 1.25
Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med (2002) 1.25
Infections in patients with aplastic anemia. Semin Hematol (2009) 1.25
Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine. J Pediatr (2008) 1.22
Dyskeratosis congenita: the first NIH clinical research workshop. Pediatr Blood Cancer (2009) 1.22
Granulocyte transfusions in severe aplastic anemia: an eleven-year experience. Haematologica (2009) 1.20
HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood (2002) 1.19
Investigation of SEN virus infection in patients with cryptogenic acute liver failure, hepatitis-associated aplastic anemia, or acute and chronic non-A-E hepatitis. J Infect Dis (2003) 1.18
Nonisotopic detection of microRNA using digoxigenin labeled RNA probes. Mol Cell Probes (2006) 1.18
Aplastic anaemia and telomerase RNA mutations. Lancet (2002) 1.17
Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades. Clin Infect Dis (2011) 1.16